The Effects of Linezolid and Vancomycin on Inflammation and Cellular Signaling Vents
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00811980|
Recruitment Status : Completed
First Posted : December 19, 2008
Last Update Posted : November 24, 2011
|Condition or disease||Intervention/treatment|
|Sepsis||Drug: Linezolid or Vancomycin|
|Study Type :||Observational|
|Actual Enrollment :||60 participants|
|Official Title:||The Effects of Linezolid and Vancomycin on Inflammation and Cellular Signaling Vents|
|Study Start Date :||January 2009|
|Actual Primary Completion Date :||June 2010|
|Actual Study Completion Date :||June 2010|
Drug: Linezolid or Vancomycin
Whole blood samples from healthy subjects will be incubated with MRSA bacterium or bacterial toxins in the presence and absence of either linezolid or vancomycin. Final concentrations will mimic physiologic conditions. Platelets and leukocytes will be isolated and assayed for the presence of absence of activation and pre-mRNA splicing.
Other Name: Zyvox
- IL-6 [ Time Frame: 12 Months ]Measurement of IL-6 release in response to MRSA.
- MCP-1 [ Time Frame: 12 Months ]Measurement of MCP-1 release in response to MRSA.
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00811980
|Principal Investigator:||Guy Zimmerman, MD||University of Utah|